Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma

Masaki, Yoshiharu; Akutsu, Noriyuki; Adachi, Yasushi; Ishigami, Keisuike; Iwata, Norikazu; Endo, Takao; Ishii, Yoshifumi; Sasaki, Yasushi; Nagayama, Masatoshi; Kimura, Yasutoshi; Nakase, Hiroshi

doi:10.1007/s12328-022-01649-x

Cited by 4 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be an unusual complication of hepatolithiasis and recurrent pyogenic cholangitis [97]. Genomic analysis of mucinous ICCA revealed that the molecular carcinogenesis of mucinous ICCA differs from that of conventional ICCA [101,102]. It tends to have a more favorable prognosis than conventional ICCA [69].…”

Section: Mucinous Carcinomamentioning

confidence: 99%

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

Choi,

Thung

2024

Preprint

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (ICCA) is a malignant epithelial neoplasm characterized by biliary differentiation within the liver. ICCA is molecularly heterogeneous and exhibits a broad spectrum of histopathological features. It is a highly aggressive carcinoma with high mortality and poor survival rates. ICCAs are classified into two main subtypes: small duct type and large duct types. These two tumor types have different cell origins and clinicopathological features. ICCAs are characterized by numerous molecular alterations, including mutations in KRAS, TP53, IDH1/2, ARID1A, BAP1, BRAF, SAMD4, and EGFR, and FGFR2 fusion. Two main molecular subtypes–inflammation and proliferation–have been proposed. Recent advances in high-throughput assays using next-generation sequencing have improved our understanding of ICCA pathogenesis and molecular genetics. The diagnosis of ICCA poses a significant challenge for pathologists because of its varied morphologies and phenotypes. Accurate diagnosis of ICCA is essential for effective patient management and prognostic determination. This article provides an updated overview of ICCA pathology, focusing particularly on molecular features, histological subtypes, and diagnostic approaches.

show abstract

Section: Mucinous Carcinomamentioning

confidence: 99%

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

Choi,

Thung

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…This may be an unusual complication of hepatolithiasis and recurrent pyogenic cholangitis [101]. Genomic analysis of mucinous ICCA revealed that the molecular carcinogenesis of mucinous ICCA differs from that of conventional ICCA [105,106]. It tends to have a more favorable prognosis than conventional ICCA [70].…”

Section: Mucinous Carcinomamentioning

confidence: 99%

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

Choi,

Thung

2024

Cancers

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (ICCA) is a malignant epithelial neoplasm characterized by biliary differentiation within the liver. ICCA is molecularly heterogeneous and exhibits a broad spectrum of histopathological features. It is a highly aggressive carcinoma with high mortality and poor survival rates. ICCAs are classified into two main subtypes: the small-duct type and large-duct types. These two tumor types have different cell origins and clinicopathological features. ICCAs are characterized by numerous molecular alterations, including mutations in KRAS, TP53, IDH1/2, ARID1A, BAP1, BRAF, SAMD4, and EGFR, and FGFR2 fusion. Two main molecular subtypes—inflammation and proliferation—have been proposed. Recent advances in high-throughput assays using next-generation sequencing have improved our understanding of ICCA pathogenesis and molecular genetics. The diagnosis of ICCA poses a significant challenge for pathologists because of its varied morphologies and phenotypes. Accurate diagnosis of ICCA is essential for effective patient management and prognostic determination. This article provides an updated overview of ICCA pathology, focusing particularly on molecular features, histological subtypes, and diagnostic approaches.

show abstract

Gimeracil/oteracil/tegafur

2022

Reactions Weekly

View full text Add to dashboard Cite

Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma

Cited by 4 publications

References 62 publications

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

Gimeracil/oteracil/tegafur

Contact Info

Product

Resources

About